APCCC 2022 | Future developments in the treatment of prostate cancer

Andrew Armstrong, MD, MS, Duke Cancer Institute, Durham, NC comments on trial updates and upcoming advancements in the field of prostate cancer treatment. Specifically, Prof. Armstrong discusses the ARASENS trial (NCT02799602) and the anticipated approval of darolutamide as a triple therapy in combination with androgen-deprivation therapy (ADT) and docetaxel. In addition, Prof. Armstrong comments on ongoing Phase III trials investigating the use of androgen receptor (AR) antagonists such as darolutamide monotherapy for mHSPC treatment. Moreover, updates from the ARCHES (NCT02677896), ENZAMET (NCT02446405) and TITAN (NCT02489318) studies are anticipated. This interview took place at the APCCC 2022 conference, held in Lugano, Switzerland.